Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Intern Med
Auteurs principaux: DeJong, Colette, Masuda, Camlyn, Chen, Randi, Kazi, Dhruv S., Dudley, R. Adams, Tseng, Chien-Wen
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2020
Sujets:
Research Letter
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7490744/
https://ncbi.nlm.nih.gov/pubmed/32926091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.2922
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires